Drugs / Samatasvir
Samatasvir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01813552 | Feb → Mar 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01852604 | Mar 2013 → Apr 2015 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01335607 Comparator | Apr → May 2011 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Press releases naming this drug 3 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Samatasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01813552 ↗ |
| Known as | IDX-18719 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039519 ↗ |
| Known as | IDX184 | “Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)” NCT01335607 ↗ |
| Known as | IDX719 | “Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.” NCT01852604 ↗ |
| Modality | Small molecule | — CHEMBL3039519 ↗ |
| Route | Oral | “100 mg single oral dose” NCT01335607 ↗ |